Navigation Links
Less-invasive Lymph Node Resection Following Breast Cancer Surgery Confirmed as Standard of Care in Eight-year Study Led by AGH Doctors
Date:6/5/2010

Women facing breast cancer surgery can now be certain that a less-invasive technique called sentinel node resection is just as safe and effective as the traditional surgery of removing all lymph nodes from the underarm area, according to a new study being presented today at the American Society of Clinical Oncology (ASCO) meeting by oncologists from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital (AGH) in Pittsburgh.

Chicago, IL (Vocus) June 5, 2010 -- Women facing breast cancer surgery can now be certain that a less-invasive technique called sentinel node resection is just as safe and effective as the traditional surgery of removing all lymph nodes from the underarm area, according to a new study being presented today at the American Society of Clinical Oncology (ASCO) meeting by oncologists from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital (AGH) in Pittsburgh.

The study represents the first long-term comparison of the two methods’ effect on breast cancer survival and recurrence, said Thomas B. Julian, MD, Associate Director of the Breast Care Center at AGH and one of the clinical trial’s principal investigators, along with Norman Wolmark, MD, who serves as Chair of both the NSABP and the Department of Human Oncology at AGH.

The study, which enrolled 5,611 women over a period of five years, showed no significant difference in overall survival, disease-free survival, or regional control of cancer between the sentinel node resection alone versus complete axillary dissection of the lymph nodes.

“Sentinel node resection is now clearly the standard of care for women with clinically node-negative breast cancer, which comprise the majority of patients,” Dr. Julian said. “Many women with this disease are now able to avoid the potential complications of full lymph node removal and know that their cancer is being effectively treated.”

Removing all lymph nodes from the underarm area carries the risk of difficult and sometimes permanent complications ,including lost sensation in the back of the arm, tingling, weakness and swelling (lymphedema).

Sentinel nodes are normally the first lymph nodes to receive drainage as well as cancer cells from the breast tumor. Doctors can find the sentinel nodes and remove them with a small surgical procedure. If no cancer is found, removal of the remaining lymph nodes is not necessary.

The NSAPB study was the largest prospective randomized Phase III trial designed to determine that sentinel node resection alone results in the same survival and regional control as axillary dissection.

Participants across North America and Puerto Rico were randomly assigned to undergo either a sentinel node resection with an axillary dissection, or to a sentinel node biopsy alone followed by axillary dissection if a sentinel node biopsy showed cancer.

Overall eight–year survival was 91.8 percent for the sentinel node-alone patients and 90.3 percent for those who also had an axillary dissection. Disease-free survival rates were 82.4 percent for the sentinel node group and 81.5 percent for the axillary group. Local and regional recurrence of cancer happened 61 times in the sentinel node group and 63 times in the axillary group.

“These results validate sentinel node resection as a safe and effective treatment for node-negative breast cancer patients,” Dr. Julian said.

###

Read the full story at http://www.prweb.com/releases/breast_cancer_surgery/sentinel_node_resection/prweb4094574.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. News brief: Contrast agent with MRI improves detection of lymph nodes metastases
2. Vitamin D Linked to Survival in Lymphoma Patients
3. A new target for lymphoma therapy
4. The Leukemia & Lymphoma Society Available to Comment on Findings Presented at American Society of Hematology Conference
5. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
6. Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkins Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data
7. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
8. Tumors hide out from the immune system by mimicking lymph nodes
9. Specific lymph node radiotherapy is well tolerated after surgery in early breast cancer patients
10. New class of drug kills lymphoma cells
11. Routine breast cancer biopsy might predict lymph node cancer spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... International Protein, ... nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton ... and nutritional scientist who was determined to create a line of products that would ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
Breaking Medicine Technology: